Topical ocular reproxalap will be used for the treatment of signs and symptoms of dry eye disease. Credit: Sofie Zbořilová / Pixabay.

The US Food and Drug Administration (FDA) has accepted Aldeyra Therapeutics’ new drug application (NDA) for topical ocular reproxalap to treat signs and symptoms of dry eye disease.

Reproxalap, a first-in-class investigational new drug candidate, is a small-molecule modulator of reactive aldehyde species (RASP) elevated in ocular and systemic inflammatory disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The regulator has assigned 23 November 2023 as the Prescription Drug User Fee Act (PDUFAs) date for its decision.

Aldeyra’s application is supported by the data obtained from five adequate and well-controlled studies.

It includes data for ocular dryness symptom score, Schirmer test, ocular redness, and Schirmer test ≥10mm responder analysis.

The application consists of activity that ranges from within minutes of giving the drug to up to 12 weeks of treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It also includes evaluation in dry eye chamber challenge and natural environment settings, crossover and parallel-group study designs.

Aldeyra stated that the investigational drug candidate had been studied in over 2,000 patients, and no clinically significant safety concerns were observed.

The most commonly reported adverse event in the trials is mild and transient instillation site irritation.

Aldeyra Therapeutics president and CEO Todd Brady said: “NDA acceptance marks a critical regulatory milestone for Aldeyra as reproxalap continues to advance toward potential regulatory approval for the treatment of dry eye disease.

“Based on data from a number of late-stage clinical trials, we believe reproxalap has the potential to address the need for a rapid and durable ophthalmic therapy for the millions of dry eye disease patients who are dissatisfied with currently available therapies.”